Viridian Therapeutics, Inc. VRDN Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Viridian Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viridian Therapeutics, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viridian Therapeutics, Inc.'s financing cash flow?
- Viridian Therapeutics, Inc. (VRDN) reported financing cash flow of $6.36M in Q1 2026.
- How has Viridian Therapeutics, Inc.'s financing cash flow changed year-over-year?
- Viridian Therapeutics, Inc.'s financing cash flow decreased by 31.0% year-over-year, from $9.21M to $6.36M.
- What is the long-term trend for Viridian Therapeutics, Inc.'s financing cash flow?
- Over 4 years (2021 to 2025), Viridian Therapeutics, Inc.'s financing cash flow has grown at a 35.9% compound annual growth rate (CAGR), from $125.28M to $426.74M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.